Amgen Inc. (NASDAQ:AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street ...

Amgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

Amgen AMGN is one of the several drug makers racing to develop the next blockbuster weight loss drug and take a share of the ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Invesco LLC slashed its Amgen holdings by 20.2%, unloading 2,310 shares worth roughly $2.85 million. This sale brought ...

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...

Guggenheim analyst Vamil Divan maintained a Hold rating on Amgen (AMGN – Research Report) yesterday and set a price target of $288.00. The company’s shares closed yesterday at ...

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

Evercore ISI analyst Umer Raffat maintained a Buy rating on Amgen (AMGN – Research Report) yesterday. The company’s shares closed yesterday at $277.49. Confident Investing Sta ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like vomiting, according to mid-stage trial results presented at a medical meeting ...